Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 3,181 - 3,200 results of 21,342 for search '(( significant ((a decrease) OR (greatest decrease)) ) OR ( significant decrease decrease ))', query time: 0.44s Refine Results
  1. 3181
    Comparison of 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> antibiotic prescription.

    Comparison of 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> antibiotic prescription. by Thomas Hanslmeier (19949694)

    Published 2024
    Subjects: “…fluoroquinolone shares decreased…”
    Save to List
    Saved in:
  2. 3182
    UTI diagnoses by sex and physician specialty (2013–2019).

    UTI diagnoses by sex and physician specialty (2013–2019). by Thomas Hanslmeier (19949694)

    Published 2024
    Subjects: “…fluoroquinolone shares decreased…”
    Save to List
    Saved in:
  3. 3183
    Funnel plot for testing asymmetry hypothesis using Freeman-Tukey double arcsine transformation for proportions.

    Funnel plot for testing asymmetry hypothesis using Freeman-Tukey double arcsine transformation for proportions. by Razieh Bidhendi-Yarandi (7139387)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 3184
    Fig 3 -

    Fig 3 - by Razieh Bidhendi-Yarandi (7139387)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 3185
    Table2_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX

    Table2_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX by Sofia Schaeffer (20379954)

    Published 2024
    “…<p>Metabolic dysfunction–associated steatotic liver disease (MASLD) is a multisystemic disease with a multifactorial pathogenesis involving dietary, environmental, and genetic factors. …”
    Save to List
    Saved in:
  6. 3186
    Table1_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX

    Table1_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX by Sofia Schaeffer (20379954)

    Published 2024
    “…<p>Metabolic dysfunction–associated steatotic liver disease (MASLD) is a multisystemic disease with a multifactorial pathogenesis involving dietary, environmental, and genetic factors. …”
    Save to List
    Saved in:
  7. 3187
    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  8. 3188
    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  9. 3189
    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  10. 3190
    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  11. 3191
    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  12. 3192
    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  13. 3193
    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  14. 3194
    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  15. 3195
    Renal (urea and creatinine) (a, b) and Liver function (ALT and AST) (c, d) test in serums of different experimental groups and body weight changes (e) on day 10.

    Renal (urea and creatinine) (a, b) and Liver function (ALT and AST) (c, d) test in serums of different experimental groups and body weight changes (e) on day 10. by Omid Mehrpour (9385929)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 3196
    (A) Changes of left ventricular ejection fraction over time in Roxadustat and ESAs groups.

    (A) Changes of left ventricular ejection fraction over time in Roxadustat and ESAs groups. by Jie Liu (15128)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 3197
    Hazard ratios for Sex across age based on unadjusted (A) and adjusted (B) Cox model. Note: shaded areas representing the 95% confidence intervals; green bars indicating the distribution of age among all patients.

    Hazard ratios for Sex across age based on unadjusted (A) and adjusted (B) Cox model. Note: shaded areas representing the 95% confidence intervals; green bars indicating the distrib... by Hui Ouyang (245739)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 3198
    Comparison of phenotypes between adult control and <i>aP2-Drp1</i><sup>f/f</sup> mice.

    Comparison of phenotypes between adult control and <i>aP2-Drp1</i><sup>f/f</sup> mice. by Yuta Ibayashi (20404811)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  19. 3199
    <i>mMgat2</i> and <i>HuMgat2</i> mice become obese when fed a HFD.

    <i>mMgat2</i> and <i>HuMgat2</i> mice become obese when fed a HFD. by J. Jose Corbalan (22439198)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 3200
    Relative permeability curve of a well in Gudong test area.

    Relative permeability curve of a well in Gudong test area. by Mengyun Li (7490870)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: